Jesse Myers
Adult Health · Encinitas, CANPI 1275788457
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,335 of the $9,430 with a category attached, or 88.4%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,793 and has fallen 60.2% since, to $1,112 in 2025. Among adult health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 420 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$970
- Sanofi$947
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$925
- Nestle Healthcare Nutrition Inc.$581
- plus $2K from 23 others
What the payments were for
- Consulting fees$7808%
- Food & beverage$8,33588%
- Education$3153%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $1,945 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $1,745 |
| Johnson & Johnson | 52 | $970 |
| Sanofi | 16 | $947 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $925 |
| Nestle Healthcare Nutrition Inc. | 26 | $581 |
| Daiichi Sankyo Inc. | 29 | $307 |
| QOL Medical, LLC | 11 | $245 |
| Regeneron Healthcare Solutions, Inc. | 7 | $202 |
| Pfizer | 8 | $202 |
| Aimmune Therapeutics, Inc. | 9 | $170 |
| Lilly USA, LLC | 7 | $164 |
| Madrigal Pharmaceuticals | 4 | $150 |
| Braintree Laboratories, Inc. | 4 | $108 |
| Vivus LLC | 5 | $106 |
| Intercept Pharmaceuticals, Inc. | 5 | $103 |
| Ardelyx, Inc. | 4 | $93 |
| Celltrion USA Inc. | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 5 | $87 |
| Merck | 4 | $72 |
| Intra-sana Laboratories | 2 | $67 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Evoke Pharma, Inc. | 1 | $24 |
| Stryker | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Gilead | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,430 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MotegrityPrucalopride Succinate | 14 | $8,492 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 94 | $5,694 |
| Pantoprazole Sodium | 54 | $921 |
| Omeprazole | 71 | $754 |
| CholestyramineCholestyramine (With Sugar) | 13 | $583 |
| Esomeprazole Magnesium | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,745 | $8,49214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in Encinitas
- Stacy GrissenEncinitas$82K
- Brittany PolizziEncinitas$35K
- Colleen HerrEncinitas$8K
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.